Lineage Cell Stock Jumps as OpRegen Shows Additional Cases Of Retinal Tissue Restoration In Mid-Stage StudyBenzinga • 06/01/21
Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen® RPE CellsBusiness Wire • 06/01/21
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/14/21
Lineage Reports First Quarter 2021 Financial Results and Highlights Significant Progress With All Three Clinical ProgramsBusiness Wire • 05/13/21
Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021Business Wire • 05/04/21
Lineage Cell's Dry Age-Related Macular Degeneration Cell Therapy Associated With Stable Or Improved VisionBenzinga • 05/03/21
OpRegen® Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic AtrophyBusiness Wire • 05/03/21
Lineage Cell (LCTX) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/29/21
Lineage to Present at the B. Riley Securities' Neuroscience Conference on April 28, 2021Business Wire • 04/26/21
Lineage Stock Gains After Licensing Pact With Immunomic Therapeutics For Cancer Immunotherapy PlatformBenzinga • 04/20/21
Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer ImmunotherapyBusiness Wire • 04/20/21
Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC PlatformBusiness Wire • 04/20/21
OpRegen® Data Update to Be Featured at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Christopher D. Riemann, MDBusiness Wire • 04/12/21
Lineage's Lead Candidate Used To Treat Patient With Retinal Disease Under Compassionate UseBenzinga • 03/29/21
Lineage Cell Therapeutics Announces Vitelliform Maculopathy Patient Treated With OpRegen® Under Named Patient Compassionate UseBusiness Wire • 03/29/21
Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic AtrophyBusiness Wire • 03/23/21
Lineage Cell Therapeutics' (LCTX) CEO Brian Culley on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/12/21